Lactate dehydrogenase inhibitors sensitize lymphoma cells to cisplatin without enhancing the drug effects on immortalized normal lymphocytes

European Journal of Pharmaceutical Sciences

Volumn 74, Issue , 2015, Pages 95-102

  Manerba, Marcella ^a   Di Ianni, Lorenza ^a   Fiume, Luigi ^a   Roberti, Marinella ^a   Recanatini, Maurizio ^a   Di Stefano, Giuseppina ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cancer cell metabolism; Cisplatin; Lactate dehydrogenase; Lymphoma cells

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GALLOFLAVIN; HISTONE H2AX; OXAMIC ACID; OXIDOREDUCTASE INHIBITOR; RAD51 PROTEIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; ISOCOUMARIN DERIVATIVE; LACTATE DEHYDROGENASE; ORGANIC COMPOUND; OXAMATE (REPELLENT); TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; EPSTEIN BARR VIRUS INFECTION; IC50; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RESPIRATORY CHAIN; SINGLE STRANDED DNA BREAK; WESTERN BLOTTING; AGONISTS; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GLYCOLYSIS; HUMAN; METABOLISM; OSMOLARITY; TRANSFORMED CELL LINE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BURKITT LYMPHOMA; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GLYCOLYSIS; HUMANS; ISOCOUMARINS; L-LACTATE DEHYDROGENASE; LYMPHOCYTES; NEOPLASM PROTEINS; ORGANIC CHEMICALS; OSMOLAR CONCENTRATION; REACTIVE OXYGEN SPECIES;

EID: 84929995952     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2015.04.022     Document Type: Article

References (49)

1. J. Billiard, J.B. Dennison, J. Briand, R.S. Annan, D. Chai, M. Colón, C.S. Dodson, S.A. Gilbert, J. Greshock, J. Jing, H. Lu, J.E. McSurdy-Freed, L.A. Orband-Miller, G.B. Mills, C.J. Quinn, J.L. Schneck, G.F. Scott, A.N. Shaw, G.M. Waitt, R.F. Wooster, and K.J. Duffy Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells Cancer Metabol. 1 2013 19
2. G. Brady, G.J. Macarthur, and P.J. Farrell Epstein-Barr virus and Burkitt lymphoma Postgrad. Med. J. 84 2008 372 377
3. Breitinger, H.G., 2012. Drug Synergy - Mechanisms and Methods of Analysis. In: Acree, B., editor: Toxicity and Drug Testing, InTech. ISBN: 978-953-51-0004-1, http://dx.doi.org/10.5772/30922. < http://www.intechopen.com/books/toxicity-and-drug-testing/drug-synergy-mechanisms-and-methods-of-analysis >.
4. M.S. Cooke, M.D. Evans, M. Dizdaroglu, and J. Lunec Oxidative DNA damage: mechanisms, mutation, and disease FASEB J. 17 2003 1195 1214
5. F. Di Meo, V. Lemaur, J. Cornil, R. Lazzaroni, J.L. Duroux, Y. Olivier, and P. Trouillas Free radical scavenging by natural polyphenols: atom versus electron transfer J. Phys. Chem. A 117 2013 2082 2092
6. G. Di Stefano, M. Manerba, and M. Vettraino NAD metabolism and functions: a common therapeutic target for neoplastic, metabolic and neurodegenerative diseases Curr. Top. Med. Chem. 13 2013 2918 2929
7. J. Ding, Z.H. Miao, L.H. Meng, and M.Y. Geng Emerging cancer therapeutic opportunities target DNA-repair systems Trends Pharm. Sci. 27 2006 338 344
8. A.M. Dorward, and G. Singh Energetic characteristics of cisplatin resistant ovarian carcinoma cells Anticancer Res. 16 1996 443 447
9. A.C. Dos Santos Ferreira, R.A. Fernandes, J.K. Kwee, and C.E. Klumb Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells J. Cancer Res. Clin. Oncol. 138 2012 317 325
10. F. Farabegoli, M. Vettraino, M. Manerba, L. Fiume, and G. Di Stefano Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways Eur. J. Pharm. Sci. 47 2012 729 738
11. B.P. Fauber, P.S. Dragovich, J. Chen, L.B. Corson, C.Z. Ding, C. Eigenbrot, S. Labadie, S. Malek, D. Peterson, H.E. Purkey, K. Robarge, S. Sideris, M. Ultsch, B. Wei, I. Yen, Q. Yue, and A. Zhou Identification of 3,6-disubstituted dihydropyrones as inhibitors of human lactate dehydrogenase Bioorg. Med. Chem. Lett. 24 2014 5683 5687
12. L. Fiume Comment on: targeting homologous recombination-mediated DNA repair in cancer Expert Opin. Ther. Targets 18 2014 833
13. L. Fiume, M. Manerba, M. Vettraino, and G. Di Stefano Inhibition of lactate dehydrogenase activity as an approach to cancer therapy Future Med. Chem. 6 2014 429 445
14. A. Gallamini, C. Zwarthoed, and A. Borra Positron emission tomography (PET) in oncology Cancers (Basel) 6 2014 1821 1889
15. R.J. Gillies, I. Robey, and R.A. Gatenby Causes and consequences of increased glucose metabolism of cancers J. Nucl. Med. 49 2008 24S 42S
16. C. Granchi, S. Bertini, M. Macchia, and F. Minutolo Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials Curr. Med. Chem. 17 2010 672 697
17. E. Hernlund, L.S. Ihrlund, O. Khan, Y.O. Ates, S. Linder, T. Panaretakis, and M.C. Shoshan Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir Int. J. Cancer 123 2008 476 483
18. L.S. Ihrlund, E. Hernlund, O. Khan, and M.C. Shoshan 3-Bromopyruvate as inhibitor of tumor cell energy metabolism and chemopotentiator of platinum drugs Mol. Oncol. 2 2008 94 101
19. E.R. Jamieson, and S.J. Lippard Structure, recognition and processing of cisplatin-DNA adducts Chem. Rev. 99 1999 2467 2498
20. T. Kanno, K. Sudo, M. Maekawa, Y. Nishimura, M. Ukita, and K. Fukutake Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy Clin. Chim. Acta 173 1988 89 98
21. M. Kartalou, and J.M. Essigmann Mechanisms of resistance to cisplatin Mutat. Res. 478 2001 23 43
22. H.L. Klein The consequences of Rad51 overexpression for normal and tumor cells DNA Repair 7 2008 686 693
23. A. Le, C.R. Cooper, A.M. Gouw, R. Dinavahi, A. Maitra, L.M. Deck, R.E. Royer, D.L. Vander Jagt, G.L. Semenza, and C.V. Dang Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression Proc. Natl. Acad. Sci. USA 107 2010 2037 2042
24. E.Y. Leung, J.E. Kim, M. Askarian-Amiri, W.R. Joseph, M.J. McKeage, and B.C. Baguleym Hormone resistance in two MCF-7 breast cancer cell lines is associated with reduced mTOR signaling, decreased glycolysis, and increased sensitivity to cytotoxic drugs Front. Oncol. 4 2014 221
25. C.Y. Li Inhibitors of DNA repair for cancer therapy, ready for prime time? Trans. Cancer Res. 1 2012 4 5
26. P. Loar, H. Wahl, M. Kshirsagar, G. Gossner, K. Griffith, and J.R. Liu Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells Am. J. Obstet. Gynecol. 202 2010 371.e1-e8
27. D.B. Longley, and P.G. Johnston Molecular mechanisms of drug resistance J. Pathol. 205 2005 275 292
28. J. Lu, M. Tan, and Q. Cai The Warburg effect in tumor progression: Mitochondrial oxidative metabolism as an anti-metastasis mechanism Cancer Lett. 356 2015 156 164
29. M. Maekawa, K. Sudo, T. Kanno, and S.S. Li Molecular characterization of genetic mutation in human lactate dehydrogenase-A (M) deficiency Biochem. Biophys. Res. Commun. 168 1990 677 682
30. M. Manerba, M. Vettraino, L. Fiume, G. Di Stefano, A. Sartini, E. Giacomini, R. Buonfiglio, M. Roberti, and M. Recanatini Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase ChemMedChem 7 2012 311 317
31. A. Marchini, R. Longnecker, and E. Kieff Epstein-Barr Virus (EBV)-negative B-lymphoma cell lines for clonal isolation and replication of EBV recombinants J. Virol. 66 1992 4972 4981
32. R. Marullo, E. Werner, N. Degtyareva, B. Moore, G. Altavilla, S.S. Ramalingam, and P.W. Doetsch Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions PLOS One 8 2013 e81162
33. H. Miyajima, Y. Takahashi, M. Suzuki, T. Shimizu, and E. Kaneko Molecular characterization of gene expression in human lactate dehydrogenase-A deficiency Neurology 43 1993 1414 1419
34. K.A. Olaussen, J. Adam, E. Vanhecke, P. Vielh, R. Pirker, L. Friboulet, H. Popper, A. Robin, F. Commo, J. Thomale, L. Kayitalire, M. Filipits, T. Le Chevalier, F. André, E. Brambilla, and J.C. Soria PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs Lung Cancer 80 2013 216 222
35. J. Papacostantinou, and S.P. Colowick The role of glycolysis in the growth of tumor cells. I. Effects of oxamic acid on the metabolism of Ehrlich tumor cells in vitro J. Biol. Chem. 236 1961 278 284
36. A. Sharma, K. Singh, and A. Almasan Histone H2AX phosphorylation: a marker for DNA damage Meth. Mol. Biol. 920 2012 613 626
37. H. Shim, C. Dolde, B.C. Lewis, C.S. Wu, G. Dang, R.A. Jungmann, R. Dalla-Favera, and C.V. Dang C-Myc transactivation of LDH-A: implications for tumor metabolism and growth Proc. Natl. Acad. Sci. USA 94 1997 6658 6663
38. Y.D. Song, K.F. Zhang, D. Liu, Y.Q. Guo, D.Y. Wang, M.Y. Cui, G. Li, Y.X. Sun, J.H. Shen, X.G. Li, L. Zhang, and F.J. Shi Inhibition of EGFR-induced glucose metabolism sensitizes chondrosarcoma cells to cisplatin Tumour Biol. 35 2014 7017 7024
39. E.J. Sullivan, M. Kurtoglu, R. Brenneman, H. Liu, and T.J. Lampidis Targeting cisplatin-resistant human tumor cells with metabolic inhibitors Cancer Chemother. Pharmacol. 73 2014 417 427
40. S.G. Swygert, and C.L. Peterson Chromatin dynamics: interplay between remodeling enzymes and histone modifications Biochim. Biophys. Acta 1839 2009 728 736
41. D. Trachootham, J. Alexandre, and P. Huang Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8 2009 579 591
42. S. Tsujno, S. Shanske, A. Keith, R.G. Haller, and S. Di Mauro Molecular genetic studies of muscle lactate dehydrogenase deficiency in white patients Ann. Neurol. 36 1994 661 665
43. M. Vettraino, M. Manerba, M. Govoni, and G. Di Stefano Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1 Anticancer Drugs 24 2013 862 870
44. R.A. Ward, C. Brassington, A.L. Breeze, A. Caputo, S. Critchlow, G. Davies, L. Goodwin, G. Hassall, R. Greenwood, G.A. Holdgate, M. Mrosek, R.A. Norman, S. Pearson, J. Tart, J.A. Tucker, M. Vogtherr, D. Whittaker, J. Wingfield, J. Winter, and K. Hudson Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation J. Med. Chem. 55 2012 3285 3306
45. J. Xie, B.S. Wang, D.H. Yu, Q. Lu, J. Ma, H. Qi, C. Fang, and H.Z. Chen Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells Int. J. Oncol. 38 2011 409 411
46. H. Xie, J. Hanai, J.G. Ren, L. Kats, K. Burgess, P. Bhargava, S. Signoretti, J. Billiard, K.J. Duffy, A. Grant, X. Wang, P.K. Lorkiewicz, S. Schatzman, M. Bousamra, A.N. Lane, R.M. Higashi, T.W. Fan, P.P. Pandolfi, V.P. Sukhatme, and P. Seth Targeting lactate dehydrogenase-A inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells Cell Metabol. 19 2014 795 809
47. F. Zhang, and R.L. Aft Chemosensitizing and cytotoxic effects of 2-deoxy-d-glucose on breast cancer cells J. Cancer Res. Ther. 5 Suppl. 1 2009 S41 S43
48. X. Zhao, T. Lwin, X. Zhang, A. Huang, J. Wang, V.E. Marquez, S. Chen-Kiang, W.S. Dalton, E. Sotomayor, and J. Tao Disruption of MYC-MiRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity Leukemia 27 2013 2341 2350
49. J.G. Zhao, K.M. Ren, and J. Tang Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism Tumour Biol. 35 2014 12305 12315